{"id":722,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/"},"modified":"2026-10-11T08:32:04","modified_gmt":"2026-10-11T08:32:04","slug":"retatrutide-phase-2-studie-zur-adipositas-338-erwachsene-48-wochen","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/de\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","title":{"rendered":"Retatrutid: Was bedeutet das 24.2%-Abnahmeergebnis?"},"content":{"rendered":"

Why did researchers study it?<\/h2>\n

Retatrutide acts at three receptors called GIP, GLP-1 and glucagon receptors. A receptor is a cell\u2019s receiving point for a signal. Having three targets explains the research interest, but the number of targets cannot tell us the size of the effect. That requires an experiment.<\/p>\n

How was the comparison made?<\/h2>\n

The trial randomly assigned adults with obesity, or overweight plus a weight-related condition, to retatrutide regimens or placebo. Placebo supplies a comparison without the active study compound. The study\u2019s main weight assessment was at week 24; participants were followed for 48 weeks. The later result should therefore be described as the week-48 result.<\/p>\n

\n
    \n
  1. 01<\/b>Study question<\/span><\/li>\n
  2. 02<\/b>338 adults<\/span><\/li>\n
  3. 03<\/b>48-week comparison<\/span><\/li>\n<\/ol>
    Reading guide: separates the study questions; not raw data or a prediction of product performance.<\/figcaption><\/figure>\n

    What happened by week 48?<\/h2>\n

    The reported average weight changes were \u22128.7%, \u221217.1%, \u221222.8% and \u221224.2% in the 1, 4, 8 and 12 mg study groups, compared with \u22122.1% for placebo. These are the trial\u2019s adjusted group estimates. The amounts identify experimental groups, not a guide to using research material. [1]<\/p>\n

    Does 24.2% mean everyone lost that much?<\/h2>\n

    No. An average summarizes a group and hides differences between individuals. As arithmetic only, 24.2% of a hypothetical starting weight of 100 kg is 24.2 kg. This explains the percentage; it does not predict anyone\u2019s result. Also compare changes at the same time point: a 24-week value and a 48-week value answer different questions.<\/p>\n

    What else needs attention?<\/h2>\n

    Digestive adverse events were the most common, and the paper also reported heart-rate changes. A benefit-only summary leaves out important information. This was a phase-2 study that explored different regimens. It was not a direct retatrutide-versus-tirzepatide comparison and cannot settle that ranking. [1]<\/p>\n

    How does this connect with research material?<\/h2>\n

    The study helps define a research question about retatrutide. It does not test an NHD catalog batch. For a laboratory project, the product link below is the next place to confirm the named material, available variants and required records. A clinical trial preparation and a research-use material are separate products.<\/p>\n

    \n

    Related research products<\/h2>\n
    \n
    \n

    Retatrutide<\/h3>\n

    Research into three metabolic receptors.<\/p>\n

    View product and variants \u2192<\/a><\/article>\n<\/div>\n

    For a material inquiry, specify the name, quantity, laboratory purpose and records needed. The team will confirm the available scope.<\/p>\n

    Discuss material requirements \u2192<\/a><\/section>\n

    \n

    Original research and reading notes<\/h2>\n
      \n
    1. Retatrutide obesity trial \u00b7 NEJM 2023<\/a><\/li>\n<\/ol>\n

      Study amounts and preparations identify experimental conditions, not recommended use. AI-assisted research explanation; sources checked 11 October 2026. NHD catalog materials are for research, development and manufacturing, not human or veterinary use.<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

      Lies die Studie mit 338 Personen, ohne ein durchschnittliches Ergebnis mit einem Versprechen zu verwechseln.<\/p>","protected":false},"author":0,"featured_media":4036,"template":"","class_list":["post-722","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nRetatrutide: What Does the 24.2% Weight-Loss Result Mean? | NHD<\/title>\n<meta name=\"description\" content=\"Read the 338-person trial without confusing an average result with a promise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/fallstudien\/retatrutide-phase-2-studie-zur-adipositas-338-erwachsene-48-wochen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide: What Does the 24.2% Weight-Loss Result Mean?\" \/>\n<meta property=\"og:description\" content=\"Read the 338-person trial without confusing an average result with a promise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/fallstudien\/retatrutide-phase-2-studie-zur-adipositas-338-erwachsene-48-wochen\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-11T08:32:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-722.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\",\"name\":\"Retatrutide: What Does the 24.2% Weight-Loss Result Mean? | NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-722.jpg\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-10-11T08:32:04+00:00\",\"description\":\"Read the 338-person trial without confusing an average result with a promise.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-722.jpg\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-722.jpg\",\"width\":1200,\"height\":800,\"caption\":\"Editorial comic illustration: Retatrutide Phase 2. Conceptual cover, not experimental imagery.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/etudes-de-cas\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Retatrutide: What Does the 24.2% Weight-Loss Result Mean?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Retatrutide: Was bedeutet das 24.2%-Abnahmeergebnis? | NHD","description":"Lies die Studie mit 338 Personen, ohne ein durchschnittliches Ergebnis mit einem Versprechen zu verwechseln.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/fallstudien\/retatrutide-phase-2-studie-zur-adipositas-338-erwachsene-48-wochen\/","og_locale":"de_DE","og_type":"article","og_title":"Retatrutide: What Does the 24.2% Weight-Loss Result Mean?","og_description":"Read the 338-person trial without confusing an average result with a promise.","og_url":"https:\/\/nhdbio.com\/de\/fallstudien\/retatrutide-phase-2-studie-zur-adipositas-338-erwachsene-48-wochen\/","og_site_name":"NHD","article_modified_time":"2026-10-11T08:32:04+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-722.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","name":"Retatrutide: Was bedeutet das 24.2%-Abnahmeergebnis? | NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-722.jpg","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-10-11T08:32:04+00:00","description":"Lies die Studie mit 338 Personen, ohne ein durchschnittliches Ergebnis mit einem Versprechen zu verwechseln.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-722.jpg","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-722.jpg","width":1200,"height":800,"caption":"Editorial comic illustration: Retatrutide Phase 2. Conceptual cover, not experimental imagery."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/fr\/etudes-de-cas\/"},{"@type":"ListItem","position":3,"name":"Retatrutide: What Does the 24.2% Weight-Loss Result Mean?"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":3,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/722\/revisions"}],"predecessor-version":[{"id":4182,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/722\/revisions\/4182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/4036"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}